For most of his 18 years at Intel, Bryce Olson has been a self-described technical evangelist, promoting the company’s desktop and server platforms and its e-commerce and web-hosting services with corporate events and sales campaigns.

Then, in 2014, he found out that he had an aggressive prostate cancer. So he turned his marketing expertise at Intel toward more personally meaningful challenges. He also wanted to promote himself as a way for scientists to try out new cancer therapies targeting specific genes. And he wanted others to learn about and take advantage of these experimental but promising treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy